Methods for treating mucopolysaccharidosis
US-2024374534-A1 · Nov 14, 2024 · US
Compositions and methods for treating patients suffering from glioma or leukemia
US11896568B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11896568-B2 |
| Application number | US-202117501692-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 14, 2021 |
| Priority date | Nov 2, 2016 |
| Publication date | Feb 13, 2024 |
| Grant date | Feb 13, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Pharmaceutical compositions, kits and methods for treating tumors such as glioma and cancers such as leukemia with (R)-2-hydroxyglutarate (R-2HG) are provided, along with therapeutic regimens including treatment of a patient suffering from glioma or leukemia with a MYC-signaling inhibitor followed by or cotemporaneous with treatment with R-2HG, and optionally other chemotherapeutic agents.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treating leukemia in a subject in need thereof, the method comprising administering to the subject a combination of: an effective amount of R-2HG; and one or more chemotherapeutic agents selected from the group consisting of all trans retinoic acid (ATRA), azacitidine (AZA), daunorubicin, and decitabine. 2. The method according to claim 1 , further comprising administering at least one agent effective for inhibiting MYC signaling prior to administering the R-2HG. 3. The method according to claim 2 , wherein the at least one agent effective for inhibiting MYC signaling is selected from the group consisting of flavopiridol, purvalanol A, SU9516, PHA 767491 HCl, SNS-032, JQ1, SGI-1776, EPZ004777, C464, SAHA, triptolide, nutlin-3a, SB220025, LY294002, VAV-939, LY-411575, VX-680, NSC71948, ABT263, VER-155008, KW-2478, SB 218078, and leflunomide. 4. The method according to claim 2 , wherein the subject is characterized by possessing a mutant form of IDH1 and/or an IDH2.
Assignees
Inventors
Classifications
- A61K31/194Primary
having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid · CPC title
Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title
specific for leukemia · CPC title
Retinoic acids {; Salts thereof} · CPC title
attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)} · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11896568B2 cover?
- Pharmaceutical compositions, kits and methods for treating tumors such as glioma and cancers such as leukemia with (R)-2-hydroxyglutarate (R-2HG) are provided, along with therapeutic regimens including treatment of a patient suffering from glioma or leukemia with a MYC-signaling inhibitor followed by or cotemporaneous with treatment with R-2HG, and optionally other chemotherapeutic agents.
- Who is the assignee on this patent?
- Univ Cincinnati
- What technology area does this patent fall under?
- Primary CPC classification A61K31/194. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Feb 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).